Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599726 | 0.79 | DYRK1A (0.41) | KDM4E | |
| SCHEMBL10488646 | 0.58 | SMN1; SMN2 (0.46) | POLB | |
| SCHEMBL10488490 | 0.57 | SMN1; SMN2 (0.45) | POLB | |
| SCHEMBL15331380 | 0.57 | CHEK1 (0.38) | — | |
| SCHEMBL27556356 | 0.55 | MAPT (0.35) | MAPK1 | |
| SCHEMBL10488470 | 0.54 | SMN1; SMN2 (0.48) | KDM4E | |
| SCHEMBL10978593 | 0.54 | SMN1; SMN2 (0.50) | POLB | |
| SCHEMBL12426562 | 0.53 | — | — | |
| SCHEMBL4705385 | 0.52 | — | — | |
| SCHEMBL18366162 | 0.50 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994529-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-12 | — | — | US | disclosed |
| US-20170152233-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152233-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | KDM4E 770/4885POLB 2844/4885MAPK1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.